---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-004120"
form_type: "8-K"
ticker: "TVTX"
cik: "0001438533"
company_name: "Travere Therapeutics, Inc."
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T17:39:52.326392+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Travere reports preliminary Q4 rev ~$52M; sparsentan PDUFA Feb 17, 2023

## Summary
- Preliminary net product sales Q4 2022 ~$52M; full year 2022 net product sales ~$201M, total revenue $212M.
- Ended 2022 with ~$450M in cash, cash equivalents, and marketable securities.
- FDA PDUFA for sparsentan in IgAN set for Feb 17, 2023; potential Q1 2023 launch if approved.
- Phase 3 PROTECT (IgAN) topline confirmatory results expected Q4 2023; DUPLEX (FSGS) topline Q2 2023.
- Phase 3 trial for pegtibatinase (HCU) to begin H2 2023; RESTORE study for CTX completion expected in 2023.

## SEC filing metadata
- accession: 0001193125-23-004120
- form_type: 8-K
- ticker: TVTX
- cik: 0001438533
- company_name: Travere Therapeutics, Inc.
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1438533/000119312523004120/0001193125-23-004120-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1438533/000119312523004120/d436263d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-004120
- JSON: https://secwatch.observer/filing/0001193125-23-004120.json
- Plain text: https://secwatch.observer/filing/0001193125-23-004120.txt

## Key facts
- Earnings Releases
  Travere Therapeutics, Inc. reported the fourth quarter ended December 31, 2022 results: revenue approximately $52 million.
  - Period: the fourth quarter ended December 31, 2022
  - Revenue: approximately $52 million
  - Result: preliminary results
  source text: the Company expects net product sales for the fourth quarter of 2022 to be approximately $52 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1438533/000119312523004120/0001193125-23-004120-index.htm
- Earnings Releases
  Travere Therapeutics, Inc. reported the fiscal year ended December 31, 2022 results: revenue $212 million.
  - Period: the fiscal year ended December 31, 2022
  - Revenue: $212 million
  - Result: preliminary results
  source text: For the fiscal year 2022, the Company expects total revenue of $212 million, inclusive of approximately $201 million in net product sales and approximately $11 million in licensing and collaboration revenue.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1438533/000119312523004120/0001193125-23-004120-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.